Learn more about treatment options, expected results, and why DBS therapy is an important addition to the treatment continuum for Parkinson’s disease.
Deep brain stimulation (DBS) from Medtronic safely and effectively manages tremor, rigidity, and bradykinesia associated with Parkinson's disease.1 It may be a therapeutic option for patients with recent or longer-standing motor complications.
Physicians should be aware that the risks associated with initial surgery may increase with clinical conditions such as:
To help ensure maximum benefits from the neurostimulation system, long-term, post-surgical management of patients is recommended.
The use of Medtronic DBS therapy for Parkinson’s disease has been studied in 5 large randomized control trials. Download our clinical summary to see the data.
Consider deep brain stimulation when a patient has:
The safety and effectiveness of this therapy has not been established for the following:
Reach U.S. clinician services for Medtronic DBS products at:
Medtronic DBS systems are MR Conditional and safe in the MR environment as long as certain conditions are met. If the conditions are not met, a significant risk is tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury including coma, paralysis, or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems at www.medtronic.com/mri or contact Medtronic at (1-800) 328-0810 for a complete list of conditions. Also review current MRI manufacturer labeling before conducting the MRI.
Medtronic DBS Therapy for Parkinson's Disease and Essential Tremor Clinical Summary, 2015.
Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. February 14, 2013; 368:610-622.